■What is molecular subtype of endometrial cacinoma?

There are two kinds of uterine cancer and endometrial carcinoma is the common one. Endometrial carcinoma can be divided into different subtypes according to histopathological characterization. The major one
is endometrioid carcinoma, which accounts for more than 80% of the incidence rate, and second more is serous carcinoma with high-risk.

Different types of endometrial cancer have different malignancies. In order to help patients to select suitable treatment, NCCN Guideline suggested that molecular analysis of endometrial carcinoma has identified four clinically significant molecular subgroups:
1. POLE
2. Microsatellite Instability-High (MSI-H)
3. Copy-Number-Low (CN-L)
4. Copy-Number-High (CN-H)

These four subtypes can distinguish different tumor characteristics and prognosis, and assist a physician in formulating more precise treatment strategies for patients.

■Why is SOFIVA Endometrial Cancer Genetic Subtypes necessary?

The treatment for endometrial cancer is mostly surgical resection followed by adjuvant therapy according to the risk of patient's cancer.
However, in the most common type of patients with endometrioid cancer, it is also possible to distinguish between good and poor prognosis, more malignant groups. However, these groups cannot be effectively distinguished by the current method of assessing the risk of cancer in patients. Current method not only may underestimate the malignancy of the patient's cancer, but also cannot determine the prognosis of patients with endometrioid cancer.
Therefore, through SOFIVA Endometrial Cancer Genetic Subtypes plus the current clinical assessment method, it is possible to more effectively and comprehensively assess the malignancy of the patient's tumor, identify the patients with the best and worst prognosis, and assist a physician in giving the most appropriate treatment respectively.

■Different types of patients have different prognosis!

■ Recommended testing time

According to the NCCN Guidelines Version 1.2023 Uterine Neoplasms Version, molecular analysis of endometrial carcinoma has identified four clinically significant molecular subgroups with differing clinical
prognoses to assess suitable treatment.

■ SOFIVA Endometrial Cancer Genetic Subtypes + Current clinical typing:

Assisting in identifying groups with the best and poor prognosis

■Classification characteristics

1. Physicians/ Nurses explain procedures and contents.

2. Sign the consent form and provide FFPE and blood sample.

3. Sample delivered to laboratory.

4. Analysis of experimental data.

5. Report is produced in 15 working days.

Q: In addition to the genotyping results, what additional information can the testing provide ?

Previous studies have showed that patients with POLE gene mutation or MMR gene abnormality (MSI-H) can benefit from immunotherapy.
Therefore, when you have need of immunotherapy, you can refer to the testing results. If you are a patient with POLE mutation or MSI-H, you may benefit from immunotherapy.

References:
1. NCCN Guidelines Uterine Neoplasms Version1.2022
2. Nature. 2013;497:67–73
3. J Clin Invest. 2016;126(6):2334-2340
4. Science. 2017;357:409–413
5. JAMA Oncol. 2019;5(10):1504–1506